Clinical Trial Update: 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating 68Ga-PSMA-11 PET/CT for influencing treatment decisions in biochemically recurrent and metastatic prostate cancer. Results are f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biochemically Recurrent Prostate Cancer
• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• 68Ga-PSMA-11 (Gallium-68 labeled PSMA-11 radiopharmaceutical)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Status: COMPLETED